Cytoreductive nephrectomy in the current treatment algorithm

The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether defer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuusk, Teele, Szabados, Bernadett, Liu, Wing Kin, Powles, Thomas, Bex, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767741/
https://www.ncbi.nlm.nih.gov/pubmed/31632471
http://dx.doi.org/10.1177/1758835919879026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767741/
https://www.ncbi.nlm.nih.gov/pubmed/31632471
http://dx.doi.org/10.1177/1758835919879026

Ejemplares similares